Sarepta Therapeutics Inc.


Analysts Say Buy Sarepta Therapeutics Inc (SRPT) Shares, Ignore Patient Deaths

Sarepta shares dropped 4% after patient deaths revealed in the FDA FAERS database.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …

Sarepta Therapeutics Inc’s (SRPT) Earnings Trigger Price Target Boost; Shares Soar 18%

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring nearly 18% in pre-market trading Thursday, after the drug maker reported solid second-quarter earnings and provided a …

Valeant Pharmaceuticals Intl Inc (VRX) Turnaround Remains an Open Question, Sarepta Therapeutics Inc (SRPT) Has Good Odds to Get Port Recommendation from FDA ADCOM

In the biotech-verse, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is riding a fresh wave of positive momentum following first quarter earnings that outclassed investors’ …

Sarepta Therapeutics Inc (SRPT) Reports Q1:17 Financial Results

Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the first quarter of 2017. “The first quarter of 2017 showed significant progress across all …

Sarepta Therapeutics Inc (SRPT): Will Payors Reimburse Exondys 51?

Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), as it appears that payors are still actively …

Analysts Wary on Valeant Pharmaceuticals Intl Inc (VRX) as Salespeople Flee, Bullish on Sarepta Therapeutics Inc (SRPT) Cash Flow Prospects

Wells Fargo and Needham are chiming in with mixed takes on biotech companies Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Sarepta Therapeutics Inc (NASDAQ:SRPT). …

Oppenheimer Stays Bullish on Sarepta Therapeutics Inc (SRPT) as the Stock Shows Signs of Weakness

Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), reiterating an Outperform rating and price target …